SOTIO’s SOT106 ADC Gets FDA Fast Track for Sarcoma
PRAGUE, Basel & Boston, Aug. 26, 2026 SOTIO Biotech announced that the U.S. Food and Drug Administration (FDA) has...
Fast Track designation
Advertisement
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
NRx Pharmaceuticals Clears FDA ANDA Review
MIAMI, August 7, 2026 NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has completed the first-cycle...
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide for MASH
GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...
Zevra Therapeutics Publishes Four-Year MIPLYFFA Real-World NPC Data
BOSTON, Aug. 3, 2026 Zevra Therapeutics, Inc. announced the publication of four-year real-world safety and effectiveness data evaluating MIPLYFFA®...
Advertisements
Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update
CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...
Zai Lab Receives FDA Orphan Drug Designation for Zoci
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
Corbus Moves CRB-701 Toward FDA Registration
NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...
Allogene Therapeutics Receives FDA RMAT Status for Cema-Cel
SOUTH SAN FRANCISCO, Calif., July 29, 2026 Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
ProMIS Neurosciences Reports Positive Phase 1b PMN310 Interim Data
CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...
Advertisement
